• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特应性皮炎中的瘙痒:对巴西圣保罗一所三级大学医院成年患者的横断面研究。

Pruritus in atopic dermatitis: a cross-sectional study of adult patients from a tertiary university hospital in São Paulo, Brazil.

作者信息

Soares Georgia Biazus, Orfali Raquel Leão, Averbach Beatriz Lacerda, Yap Qai Ven, Yosipovitch Gil, Aoki Valeria

机构信息

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Department of Dermatology, Faculty of Medicine, Universidade de São Paulo, São Paulo, SP, Brazil.

出版信息

An Bras Dermatol. 2025 Jul-Aug;100(4):101093. doi: 10.1016/j.abd.2024.09.006. Epub 2025 Mar 11.

DOI:10.1016/j.abd.2024.09.006
PMID:40074665
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12346060/
Abstract

BACKGROUND

Chronic pruritus is the defining symptom of atopic dermatitis (AD). Although AD is common in Latin America, there is little data regarding pruritus intensity, characteristics, and effects on quality of life in this population.

OBJECTIVE

This cross-sectional study aimed to evaluate pruritus in 91 patients with AD at a tertiary university hospital in São Paulo, Brazil. Patients aged 14‒65-years old were included in this study.

METHODS

Patients completed the Itch Questionnaire, the ItchyQoL, and the POEM questionnaires and were asked to rate their itch severity using a 10-point peak pruritus Numerical Rating Scale (NRS). AD severity was assessed via the EASI and the vIGA-AD.

RESULTS

The mean age was 29.68 ± 12.87years, and 56.0% of patients were White. 97.8% of patients were currently experiencing pruritus with an average NRS of 7.32 ± 2.22. Patients had associated bleeding (71.4%), heat sensation (63.7%), and pain (54.9%). Worsening factors included stress (93.4%), dry skin (91.2%), and sweat (75.8%). The mean total ItchyQoL score was 78.93 ± 17.20. Female gender was significantly associated with a higher total ItchyQoL score (p = 0.009). Pruritus on the neck, foot, and whole body was associated with higher total ItchyQoL scores in adjusted models (p < 0.05). The EASI, vIGA-AD, and POEM were moderately correlated with itch intensity (r = 0.434, 0.406, and 0.610) and total ItchyQoL score (r = 0.425, 0.436, and 0.631).

STUDY LIMITATIONS

The predominantly White population cohort may not be representative of the diverse AD phenotypes in the Brazilian patient population. Children under the age of 14 and adults over the age of 65 were excluded from the population cohort. Furthermore, patients included in the study may suffer from other non-dermatological diseases that cause itch, which may influence the outcomes oberserved.

CONCLUSIONS

Patients with AD in Brazil experience significant pruritus that impacts their quality of life. Gender, body location of itch, associated pain, and stress should all be taken into consideration when evaluating AD patients with pruritus.

摘要

背景

慢性瘙痒是特应性皮炎(AD)的主要症状。尽管AD在拉丁美洲很常见,但关于该人群瘙痒强度、特征及其对生活质量影响的数据却很少。

目的

这项横断面研究旨在评估巴西圣保罗一家三级大学医院的91例AD患者的瘙痒情况。本研究纳入了年龄在14至65岁之间的患者。

方法

患者完成了瘙痒问卷、瘙痒生活质量问卷(ItchyQoL)和皮肤病生活质量指数(POEM)问卷,并被要求使用10分制的瘙痒峰值数字评定量表(NRS)对瘙痒严重程度进行评分。通过湿疹面积和严重程度指数(EASI)和医师整体评估特应性皮炎(vIGA-AD)评估AD的严重程度。

结果

平均年龄为29.68±12.87岁,56.0%的患者为白人。97.8%的患者目前正在经历瘙痒,平均NRS评分为7.32±2.22。患者伴有出血(71.4%)、热感(63.7%)和疼痛(54.9%)。加重因素包括压力(93.4%)、皮肤干燥(91.2%)和出汗(75.8%)。ItchyQoL总评分的平均值为78.93±17.20。女性性别与较高的ItchyQoL总评分显著相关(p = 0.009)。在调整模型中,颈部、足部和全身的瘙痒与较高的ItchyQoL总评分相关(p < 0.05)。EASI、vIGA-AD和POEM与瘙痒强度(r = 0.434、0.406和0.610)以及ItchyQoL总评分(r = 0.425、0.436和0.631)呈中度相关。

研究局限性

以白人为主的人群队列可能无法代表巴西患者群体中多样的AD表型。14岁以下儿童和65岁以上成年人被排除在人群队列之外。此外,纳入研究的患者可能患有其他导致瘙痒的非皮肤病,这可能会影响观察到的结果。

结论

巴西的AD患者经历了严重的瘙痒,这影响了他们的生活质量。在评估有瘙痒症状的AD患者时,应考虑性别、瘙痒的身体部位、相关疼痛和压力等因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2a/12346060/871d74c5486f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2a/12346060/70f560a5e703/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2a/12346060/871d74c5486f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2a/12346060/70f560a5e703/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c2a/12346060/871d74c5486f/gr2.jpg

相似文献

1
Pruritus in atopic dermatitis: a cross-sectional study of adult patients from a tertiary university hospital in São Paulo, Brazil.特应性皮炎中的瘙痒:对巴西圣保罗一所三级大学医院成年患者的横断面研究。
An Bras Dermatol. 2025 Jul-Aug;100(4):101093. doi: 10.1016/j.abd.2024.09.006. Epub 2025 Mar 11.
2
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies.芦可替尼乳膏单药治疗改善了轻至中度特应性皮炎成人和青少年的症状及生活质量:两项III期研究的患者报告结果
Am J Clin Dermatol. 2025 Jan;26(1):121-137. doi: 10.1007/s40257-024-00901-z. Epub 2024 Nov 15.
3
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
4
Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry.在中度至重度特应性皮炎患者中启动度普利尤单抗治疗后观察到的完全/近乎完全瘙痒缓解:来自PROSE注册研究的3年真实世界中期数据。
Dermatol Ther (Heidelb). 2025 Jun;15(6):1523-1531. doi: 10.1007/s13555-025-01395-1. Epub 2025 Apr 15.
5
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).使用乐必妥单抗和外用糖皮质激素联合治疗中重度特应性皮炎的长期管理:在日本进行的一项为期68周的随机双盲安慰剂对照III期试验(ADhere-J)
Br J Dermatol. 2025 Mar 18;192(4):597-610. doi: 10.1093/bjd/ljae394.
6
Towards a patient-centred definition for atopic dermatitis flare: a qualitative study of adults with atopic dermatitis.迈向以患者为中心的特应性皮炎发作定义:一项特应性皮炎成人患者的定性研究。
Br J Dermatol. 2024 Jun 20;191(1):82-91. doi: 10.1093/bjd/ljae037.
7
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.与安慰剂(“Measure Up 1”和“Measure Up 2”研究)及度普利尤单抗(“Heads Up”研究)相比,乌帕替尼可快速改善瘙痒并清除皮肤症状:三项针对中度至重度特应性皮炎患者的3期临床试验结果
Dermatol Ther (Heidelb). 2025 Jun 2. doi: 10.1007/s13555-025-01443-w.
8
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.中重度特应性皮炎患者从度普利尤单抗转换为阿布昔替尼治疗:JADE DARE研究中使用度普利尤单抗治疗后疗效的事后分析
Dermatol Ther (Heidelb). 2025 Feb;15(2):367-380. doi: 10.1007/s13555-024-01320-y. Epub 2025 Feb 4.
9
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
10
Cross-sectional burden-of-illness study in atopic dermatitis (MEASURE-AD) in Australia and New Zealand reveals impacts on well-being.在澳大利亚和新西兰进行的特应性皮炎(MEASURE-AD)横断面疾病负担研究揭示了对健康的影响。
Australas J Dermatol. 2024 Sep;65(6):e145-e155. doi: 10.1111/ajd.14308. Epub 2024 May 21.

本文引用的文献

1
Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique.特应性皮炎治疗管理的共识——巴西皮肤病学会:利用电子德尔菲技术更新光疗和系统治疗。
An Bras Dermatol. 2023 Nov-Dec;98(6):814-836. doi: 10.1016/j.abd.2023.04.003. Epub 2023 Jun 9.
2
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient Survey.特应性皮炎的疾病负担与未满足的需求:一项患者调查结果
Dermatitis. 2023 Mar-Apr;34(2):135-144. doi: 10.1089/derm.2022.29015.jsi. Epub 2023 Jan 18.
3
Predictive factors of quality of life in chronic pruritus patients: A cross-sectional study.
慢性瘙痒患者生活质量的预测因素:一项横断面研究。
JAAD Int. 2023 Jan 4;11:65-71. doi: 10.1016/j.jdin.2022.12.005. eCollection 2023 Jun.
4
Healthcare Disparities in Atopic Dermatitis in Latin America: A Narrative Review.拉丁美洲特应性皮炎的医疗保健差异:一项叙述性综述。
Dermatol Ther (Heidelb). 2023 Feb;13(2):399-416. doi: 10.1007/s13555-022-00875-y. Epub 2022 Dec 23.
5
Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes.采用患者报告结局评估日本特应性皮炎瘙痒负担。
J Med Econ. 2021 Jan-Dec;24(1):1280-1289. doi: 10.1080/13696998.2021.2002559.
6
The Unmet Needs in Atopic Dermatitis Control in Latin America: A Multidisciplinary Expert Perspective.拉丁美洲特应性皮炎控制方面未满足的需求:多学科专家视角
Dermatol Ther (Heidelb). 2021 Oct;11(5):1521-1540. doi: 10.1007/s13555-021-00595-9. Epub 2021 Aug 27.
7
Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients.头颈部严重程度指数与特应性皮炎患者生活质量的显著恶化相关。
Exp Dermatol. 2021 Nov;30(11):1717-1718. doi: 10.1111/exd.14368. Epub 2021 May 31.
8
Itch in skin of colour: a multicentre cross-sectional study.有色人种皮肤瘙痒:一项多中心横断面研究。
Br J Dermatol. 2021 Sep;185(3):652-654. doi: 10.1111/bjd.20403. Epub 2021 Jun 6.
9
Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: A prospective observational study.采用联合瘙痒和皮损严重程度对特应性皮炎进行临床表型分析:一项前瞻性观察研究。
Ann Allergy Asthma Immunol. 2021 Jul;127(1):83-90.e2. doi: 10.1016/j.anai.2021.03.019. Epub 2021 Apr 2.
10
Quality of Life and Psychological Impact in Patients with Atopic Dermatitis.特应性皮炎患者的生活质量和心理影响
J Clin Med. 2021 Mar 21;10(6):1298. doi: 10.3390/jcm10061298.